Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities. | Annals of General Hospital Psychiatry BioMed Central Review Open Access Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities Kimberly D McLaren and Lauren B Marangell Address Mood Disorders Center Menninger Department of Psychiatry Baylor College of Medicine Houston TX USA Email Kimberly D McLaren - kmclarenmd@ Lauren B Marangell - laurenm@ Corresponding author Published 22 April 2004 Received 21 August 2003 Accepted 22 April 2004 Annals of General Hospital Psychiatry 2004 3 7 This article is available from http content 3 1 7 2004 McLaren and Marangell licensee BioMed Central Ltd. This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Background The pharmacological treatment of bipolar disorder has dramatically improved with multiple classes of agents being used as mood-stabilizers including lithium anticonvulsants and atypical antipsychotics. However the use of these medications is not without risk particularly when a patient with bipolar disorder also has comorbid medical illness. As the physician who likely has the most contact with patients with bipolar disorder psychiatrists must have a high index of suspicion for medical illness as well as a basic knowledge of the risks associated with the use of medications in this patient population. Methods A review of the literature was conducted and papers addressing this topic were selected by the authors. Results and discussion Common medical comorbidities and treatment-emergent illnesses including obesity diabetes mellitus dyslipidemia cardiac disease hepatic disease renal disease pulmonary disease and cancer are reviewed with respect to concomitant use of mood stabilizers. Guidance to clinicians regarding effective monitoring and treatment is offered. Conclusions .
